The 1,25-dihydroxyvitamin D3 [1,2vitamin D3] analog KH1060 exerts very potent effects on cell proliferation and cell differentiation via the vitamin D receptor (VDR). However, the activities of KH1060 are not associated with an increased affinity for the VDR. We now show that increased stabilization of the VDR-KH1060 complex could be an explanation for its high potencies. VDR half-life studies performed with cycloheximide-translational blocked rat osteoblast-like ROS 17/2.8 cells demonstrated that, in the absence of ligand, VDR levels rapidly decreased. After 2 hr, less than 10% of the initial VDR level could be measured. In the presence of 1,25-(OH)2vitamin D3, the VDR half-life was 15 hr. After 24 hr, less than 20% of the initial VDR content was detectable, whereas, at this time-point, when the cells were incubated with KH1060 80% of the VDR was still present. Differences in 1,25-(OH)2vitamin D3-and KH1060-induced conformational changes of the VDR could underlie the increased VDR stability. As assessed by limited proteolytic digestion analysis, both 1,25-(OH)2vitamin D3 and KH1060 caused a specific conformational change of the VDR. Compared with 1,25-(OH)2vitamin D3, KH1060 induced a conformational change that led to a far more dramatic protection of the VDR against proteolytic degradation. In conclusion, the altered VDR stability and the possibly underlying change in VDR conformation caused by KH1060 could be an explanation for its enhanced bioactivity.
Besides the traditional effects on calcium and phosphate metabolism (1) , the effects of 1,25-dihydroxyvitamin D3 [1, 2vitamin D3] on cellular differentiation and proliferation and on immunological processes (2) might have relevance for the treatment of hyperproliferative and autoimmune diseases. However, the side effects (hypercalcemia and hypercalciuria) induced by the high doses needed to achieve these effects limit the use of 1,25-(OH)2vitamin D3 in clinical practice. This has prompted the development of new 1,25-(OH)2vitamin D3 analogs with reduced calcemic activity.
Previous studies have shown that modifications in the side chain of the 1,25-(OH)2vitamin D3 molecule can lead to far more potent analogs. One of the most potent analogs until now, 20-Epi-22-oxa-24a,26a,27a-tri-homo-1,25-(OH)2vitamin D3 (KH1060) (3) , is a strong inhibitor of tumor cell growth (4, 5) and an inducer of cell differentiation (4, 6, 7) . KH1060 also exhibits strong immunosuppressive activity in both in vitro and in vivo studies (4, 8, 9) . Furthermore, KH1060 is more potent than 1,25-(OH)2vitamin D3 in stimulating in vivo and in vitro bone resorption and osteoclast recruitment in murine bone marrow cultures (4, 7, 10) .
The differences in biological activity between 1,25-(OH)2vitamin D3 and KH1060 could not be explained by an increased affinity for the vitamin D receptor (VDR) (4, 5, 7) . However, the presence of a (functional) VDR is essential for the biological responses of 1,25-(OH)2vitamin D3 and KH1060 (7, 11, 12) . It is known that, through binding to the VDR, 1,25-(OH)2vitamin D3 stabilizes the receptor (13) (14) (15) . Since VDR stabilization might influence biological activity of the ligand, we studied the effect of KH1060 on the VDR half-life in ROS 17/2.8 osteoblastic cells. We examined the effect of KH1060 on the conformation of the VDR. An 1,25-(OH)2vitamin D3 analog with normal stereochemistry at C-20 but, like KH1060, with an oxygen atom at the C-22 position, 22-oxa-calcitriol (OCT) was used as a reference compound in this study.
MATERIALS AND METHODS
Reagents. 1,25-(OH)2vitamin D3 and the analog KH1060 were generously provided by L. Binderup 
RESULTS
Differences in VDR Affinity and in Vitro Effects Between 1,25-(OH)2vitamin D3, OCT, and KH1060. To emphasize the differences in biological potencies between 1,25-(OH)2vitamin D3 and the analogs a summary of two biological responses is presented in Table 1 . In addition, the relative affinity of the analogs for the VDR is shown. The effects of OCT, KH1060, and 1,25-(OH)2vitamin D3 on the production of the bone matrix protein osteocalcin by the ROS 17/2.8 osteoblastic cells and on in vitro bone resorption are shown as examples, but KH1060 was more potent than 1,25-(OH)2vitamin D3 in other responses, whereas OCT was equipotent (7). Despite these increased potencies, KH1060 displayed reduced affinity for the VDR extracted from ROS 17/2.8 cells. In other osteoblastic cells (human osteosarcoma MG63 cells) (7) and in cells not directly related to bone metabolism (e.g., the human breast cancer cell line MCF-7) (5), a reduced VDR affinity of KH1060 compared with 1,25-(OH)2vitamin D3 was observed.
VDR Half-Life in Rat Osteoblast-Like Cells. When no ligand was present, the VDR in ROS 17/2.8 cells was almost completely degraded within 4 hr (half-life = 1.5 hr) (Fig. 2) . However, when the cells were incubated with 1,25-(OH)2vitamin D3, the VDR half-life was prolonged by 13.5 hr. Less than 20% of the initial VDR level could be detected after 24 hr. A comparable result was obtained when the cells were treated with OCT. KH1060 had a much stronger stabilizing effect on the VDR. After 24 hr, still 80% of the initial VDR level was detectable. After 48 hr of incubation, a rebound effect was observed: The control-, 1,25-(OH)2vitamin D3-, and OCT-incubated cells regained their VDR synthesis, but the VDR content was still lower than the starting level. At this time point, KH1060-incubated cells contained VDR levels comparable to the starting point levels (data not shown).
Limited Proteolytic Digestion of in Vitro Synthesized VDR Protein. The increased VDR half-life could be the result of a conformational change of the VDR. We used partial enzymatic digestion of in vitro synthesized human VDR as a means to gain insight into ligand-induced conformational changes of the VDR. The rationale behind this technique is that a changed VDR conformation will lead to a changed accessibility of cleavage sites within the VDR molecule. So, changes in VDR conformation will lead to an altered VDR digestion. In vitro synthesized [35S]methionine-labeled VDR protein was separated by SDS/PAGE into three bands of 51, 48, and 45 kDa (Fig. 3A) , probably representing different forms (e.g., phosphorylated) of the VDR. Immunoblot analysis revealed that all three proteins were immunoreactive with the IVG8C1 1 antibody to the VDR (see Fig. 7 ). When trypsin was added, two distinct fragments of 32 and 27 kDa appeared (Fig. 3A) . Increasing the trypsin concentration to 50 ,ug/ml led to a complete degradation of the VDR. When VDR was incubated with 1,25-(OH)2vitamin D3 before trypsin treatment, degradation was retarded, resulting in more persistent fragments (Fig. 3A) . Compared with 1,25-(OH)2vitamin D3, VDR treatment with OCT resulted in a similar protection against proteolysis (Fig. 3) , whereas incubation of VDR with KH1060 resulted in a dramatic increase in the resistance against protease activity (Fig. 3) . To further illustrate the large difference in potency to protect the VDR against protease activity between 1,25-(OH)2vitamin D3 and KH1060, we extended the trypsin concentration range and found that, at a trypsin concentration of 500 ,ug/ml, fragments were still detectable when the VDR was incubated with KH1060, whereas 1,25-(OH)2vitamin D3-incubated VDR was already completely degraded at a trypsin concentration of 150 ,ug/ml (Fig. 4) . Notice that in the KH1060-incubated VDR, a third ts . . fragment of -24 kDa is present that could not be detected when VDR was incubated with 1,25-(OH)2vitamin D3 or OCT (Figs. 3A and 4 ). This 24-kDa fragment could be the result of processing of the larger fragments.
The observed protection was not due to direct blockade of specific cleavage sites of trypsin, since with chymotrypsin (Fig.  5) The ligand-induced conformational change of the VDR was ligand-concentration dependent (Fig. 6) . Furthermore, the conformational change was ligand-specific. Incubating the VDR with the noncognate ligands all-trans retinoic acid, progesterone, 17/3-estradiol, thyroid hormone, and 9-cis retinoic acid did not result in an increased preservation of distinct VDR fragments (data not shown).
To exclude the possibility that the observed protection was due to direct inactivation of the protease by 1,25-(OH)2vitamin D3 or the analogs, we performed time course studies. Adding KH1060 and trypsin simultaneously did not result in an increased protection against proteolytic degradation, whereas a 10 min preincubation with KH1060 was effective (data not shown).
The observed differences in protective effect between 1,25-(OH)2vitamin D3, OCT, and KH1060 was not specific for the incubation temperature routinely used in this study (room temperature). When the temperature during the ligand and the trypsin incubation period was raised to 37°C, KH1060 was still much more potent than 1,25-(OH)2vitamin D3 in protecting the VDR against proteolytic breakdown (data not shown). (Fig. 7) .
DISCUSSION
It is known that modifications in the side chain of the 1,25-(OH)2vitamin D3 molecule can result in analogs with increased biological activity. One of these interesting 1,25-(OH)2vitamin D3 analogs, KH1060, is a much more potent regulator of cell proliferation and differentiation (4, 5, 7) . However, the mechanism(s) underlying the differences in potency remain unclear.
The increased potency of KH1060 is not associated with an increased affinity for the VDR (5, 7) , although the presence of the receptor is essential for the effects on cell proliferation and differentiation (7) . The present study demonstrates that, compared with 1,25-(OH)2vitamin D3, KH1060 increases the half-life of the VDR, which could provide an explanation for the increased biological potencies of KH1060. Binding of KH1060 to the VDR causes an almost complete stabilization of the VDR, whereas with 1,25-(OH)2vitamin D3 after 24 hr only 20% of the initial amount of VDR was present. Earlier studies showed that 1,25-(OH)2vitamin D3 or naturally occurring 1,25-(OH)2vitamin D3 metabolites stabilized the VDR in LLC-PK1 pig kidney cells (13) , mouse fibroblasts, rat intestinal epithelial cells (14) , and ROS 17/2.8 cells (15) . Our data are consistent with the VDR half-life of 2 hours in the absence of 1,25-(OH)2vitamin D3 reported by Arbour et al. (15) . They also observed a VDR stabilization when the ROS 17/2.8 cells were treated with 1,25-(OH)2vitamin D3. However, they were not able to determine a VDR half-life, since the VDR content was unchanged within the 6 (19) , hormone-induced conformational changes might be crucial for DNA binding, dimerization, and transcriptional activation, but in addition it could also play a role in receptor stability. We used partial enzymatic digestion of in vitro synthesized human VDR protein as a means to gain insight into ligand-induced conformational changes of the VDR. Partial enzymatic digestion has proven to be a useful method for studying conformational changes of the VDR (20) (21) (22) and other members of the steroid receptor superfamily (19, (22) (23) (24) (25) (26) . As we show here, incubation of the VDR with ligand leads to a conformational change of the receptor. Incubation with 1,25-(OH)2vitamin D3, KH1060, or OCT resulted in the protection against proteolytic breakdown of specific fragments of the VDR. This protection was not due to a direct effect of the ligand on the enzymes. In contrast to a 10 or 20 min preincubation with ligand, simultaneous addition of ligand and protease did not cause enhanced protection against degradation of the VDR. Also, it was not the result of blockade of specific cleavage sites by the ligands because with three different proteases similar results were obtained. In this respect, it is noteworthy that the ligand binding domain of the VDR contains over 20 evenly distributed cleavage sites for trypsin. Therefore, it seems unlikely that a relatively small molecule like 1,25-(OH)2vitamin D3 is able to protect a 32-kDa fragment from proteolytic degradation via direct blockade of these cleavage sites. The protection against protease activity could only be achieved when the receptor was incubated with its cognate ligand: VDR was not protected by 17f3-estradiol, progesterone, all-trans retinoic acid, thyroid hormone, and 9-cis retinoic acid.
In an attempt to identify the VDR fragments that are protected by ligand incubation, we performed immunoblot analysis. None of the fragments were immunoreactive with the IVG8C11 antibody, which epitope has been mapped to amino acids 57 to 164 (27) , encompassing the second zinc finger of the DNA binding domain (amino acids 21-87) and most of the hinge region (amino acids 88-188) (Fig. 7) . Furthermore, the theoretically calculated molecular weight of the ligand binding domain of the VDR is about 30 kDa, which is indeed comparable to the size of the major VDR degradation product. This suggests that the protected fragments are predominantly part of the ligand binding domain. As we do not possess specific antibodies against this region of the VDR, we cannot provide proof of this. For the progesterone receptor, a progesteroneinduced 30-kDa fragment and for the estrogen receptor an estrogen-induced 32-kDa fragment, both corresponding to their ligand binding domains, were reported (19) .
The observation that 1,25-(OH)2vitamin D3, OCT, and KH1060 induce a conformational change of in vitro synthesized VDR, leading to enhanced resistance against protease activity, makes it tempting to speculate about the role of VDR conformation in its stabilization. As shown in Figs. 3A, 4 , and 5, KH1060 is much more potent than 1,25-(OH)2vitamin D3 and OCT in the protection against proteolytic degradation. This is further illustrated when the major degradation, a 32-kDa fragment, was quantified and plotted against the protease concentration (Fig. 3B) . At high protease concentrations with KH1060, a 24-kDa VDR fragment was found that was not observed after incubation with 1,25-(OH)2vitamin D3 or OCT (Fig. 4) . Most of the conformational analyses were performed at room temperature, but, at 37°C, the difference between KH1060 and 1,25-(OH)2vitamin D3 was present, indicating that the observed phenomenon also holds at a physiological more relevant temperature. Together these data indicate a different VDR conformation after binding KH1060, which can be involved in the increased VDR stabilization observed in cells. This is even more likely when the background of the receptor conformational analysis is taken into account: protection against proteolytic breakdown due to reduced accessibility of cleavage sites in the receptor by ligand binding. Moreover, in the VDR conformational studies, 1,25-(OH)2vitamin D3 and OCT showed similar effects and induced a comparable increase in VDR half-life (Figs. 2, 3, and 5 ).
Based on the observed different effects between OCT and KH1060 on VDR half-life and VDR conformation, we conclude that only specific alterations in the side chain structure of the 1,25-(OH)2vitamin D3 molecule result in more potent analogs. The reported in vitro (Table 1 ) and in vivo biological effects of OCT (7, (28) (29) (30) (31) and the data presented here with respect to its effect on VDR half-life and VDR conformation (Figs. 2, 3 , and 5) show that substitution of the C-22 by an oxygen atom results in an analog that mimics most of the activities of 1,25-(OH)2vitamin D3. Therefore, we conclude that the potent effect of KH1060 is not the result of the substituted oxygen atom at C-22, but is probably due to (combinations with) other modifications in the side chain.
In view of the fact that stabilization and conformational change of the VDR could be responsible for increased receptor-mediated responses in target cells (15, 19) , the present study provides a means by which KH1060 can exert biological responses more potently than 1,25-(OH)2vitamin D3. In this respect, the report by Sasaki et al. (32) is of interest. They speculated that the higher biological activity of the analog 26,26,26,27,27,27-hexafluoro-1,25-(OH)2vitamin D3 could (partly) be due to a structural change of the VDR induced by this analog, leading to enhanced binding affinity of the VDR for the vitamin D response element and subsequently to enhanced transcriptional activity. It should, however, be taken into account that in addition also pharmacokinetic aspects (e.g., in relation to vitamin D binding protein affinity or altered metabolism) may contribute to the increased bioactivity of KH1060 (33) and other 20-epi-analogs (34) .
